Hasil Pencarian - Jonathan Cebon

  • Menampilkan 1 - 16 hasil dari 16
Perbaiki Hasil
  1. 1
    Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature

    Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature oleh Ashray Gunjur, Oliver Klein, Damien Kee, Jonathan Cebon

    Diterbitkan 2019-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Characterising the phenotypic evolution of circulating tumour cells during treatment

    Characterising the phenotypic evolution of circulating tumour cells during treatment oleh Simon Chang-Hao Tsao, Jing Wang, Yuling Wang, Andreas Behren, Jonathan Cebon, Matt Trau

    Diterbitkan 2018-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle–Associated PDGFRβ

    Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle–Associated PDGFRβ oleh Laura J. Vella, Andreas Behren, Bradley Coleman, David W. Greening, Andrew F. Hill, Jonathan Cebon

    Diterbitkan 2017-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma.

    A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma. oleh Lisa M Ebert, Sarah E MacRaild, Damien Zanker, Ian D Davis, Jonathan Cebon, Weisan Chen

    Diterbitkan 2012-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation

    PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation oleh Candani S. A. Tutuka, Miles C. Andrews, John M. Mariadason, Paul Ioannidis, Christopher Hudson, Jonathan Cebon, Andreas Behren

    Diterbitkan 2017-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report

    Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report oleh Sebastian Hultin, Kazi Nahar, Alexander M. Menzies, Georgina V. Long, Suran L. Fernando, Victoria Atkinson, Jonathan Cebon, Muh Geot Wong

    Diterbitkan 2020-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette–Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma

    Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette–Guérin followed by Ipilimumab in Patients with Advanced Metastat... oleh Jessica Da Gama Duarte, Jessica Da Gama Duarte, Jessica Da Gama Duarte, Sagun Parakh, Sagun Parakh, Sagun Parakh, Miles C. Andrews, Miles C. Andrews, Miles C. Andrews, Miles C. Andrews, Katherine Woods, Katherine Woods, Katherine Woods, Anupama Pasam, Anupama Pasam, Anupama Pasam, Candani Tutuka, Candani Tutuka, Candani Tutuka, Simone Ostrouska, Simone Ostrouska, Jonathan M. Blackburn, Jonathan M. Blackburn, Andreas Behren, Andreas Behren, Andreas Behren, Jonathan Cebon, Jonathan Cebon, Jonathan Cebon

    Diterbitkan 2018-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma

    PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma oleh Sagun Parakh, Sagun Parakh, Sagun Parakh, Ashan Musafer, Ashan Musafer, Sabrina Paessler, Tom Witkowski, Tom Witkowski, Connie S. N. Li Wai Suen, Candani S. A. Tutuka, Matteo S. Carlino, Matteo S. Carlino, Alexander M. Menzies, Alexander M. Menzies, Richard A. Scolyer, Richard A. Scolyer, Richard A. Scolyer, Jonathan Cebon, Jonathan Cebon, Jonathan Cebon, Alexander Dobrovic, Alexander Dobrovic, Georgina V. Long, Georgina V. Long, Georgina V. Long, Oliver Klein, Oliver Klein, Andreas Behren, Andreas Behren, Andreas Behren

    Diterbitkan 2021-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538

    Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538 oleh Oliver Klein, Clare Senko, Matteo S Carlino, Ben Markman, Louise Jackett, Bo Gao, Caroline Lum, Damien Kee, Andreas Behren, Jodie Palmer, Jonathan Cebon

    Diterbitkan 2021-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide

    Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide oleh Kok Fei Chan, Benjamin S. Gully, Stephanie Gras, Dennis X. Beringer, Lars Kjer-Nielsen, Jonathan Cebon, James McCluskey, Weisan Chen, Jamie Rossjohn

    Diterbitkan 2018-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial

    Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial oleh Linda Mileshkin, Ben Markman, Oliver Klein, Damien Kee, Jonathan Cebon, Andreas Behren, Matteo Carlino, Bo Gao, Jessica da Gama Duarte, Luke Quigley, Louise Jackett, Richelle Linklater, Andrew Strickland, Clare Scott, Jodie Palmer

    Diterbitkan 2021-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma

    A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma oleh Surein Arulananda, Megan O’Brien, Marco Evangelista, Laura J. Jenkins, Ashleigh R. Poh, Marzena Walkiewicz, Trishe Leong, John M. Mariadason, Jonathan Cebon, Srividya B. Balachander, Justin R. Cidado, Erinna F. Lee, Thomas John, Walter D. Fairlie

    Diterbitkan 2021-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigen.

    A novel HLA-B18 restricted CD8+ T cell epitope is efficiently cross-presented by dendritic cells from soluble tumor antigen. oleh Rona Y Zhao, Nicole A Mifsud, Kun Xiao, Kok-Fei Chan, Sara Oveissi, Heather M Jackson, Nektaria Dimopoulos, Philippe Guillaume, Ashley J Knights, Tamara Lowen, Neil C Robson, Sarah E Russell, Emmanuel Scotet, Ian D Davis, Eugene Maraskovsky, Jonathan Cebon, Immanuel F Luescher, Weisan Chen

    Diterbitkan 2012-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma

    Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma oleh Surein Arulananda, Megan O’Brien, Marco Evangelista, Tiffany J. Harris, Nikita S. Steinohrt, Laura J. Jenkins, Marzena Walkiewicz, Robert J. J. O’Donoghue, Ashleigh R. Poh, Bibhusal Thapa, David S. Williams, Trishe Leong, John M. Mariadason, Xia Li, Jonathan Cebon, Erinna F. Lee, Thomas John, W. Douglas Fairlie

    Diterbitkan 2021-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Correction: Frequent Mutations in Human Melanoma.

    Correction: Frequent Mutations in Human Melanoma. oleh Otavia L. Caballero, Qi Zhao, Donata Rimoldi, Brian J. Stevenson, Suzanne Svobodová, Sylvie Devalle, Ute F. Röhrig, Anna Pagotto, Olivier Michielin, Daniel Speiser, Jedd D. Wolchok, Cailian Liu, Tanja Pejovic, Kunle Odunsi, Francis Brasseur, Benoit J. Van den Eynde, Lloyd J. Old, Xin Lu, Jonathan Cebon, Robert L. Strausberg, Andrew J. Simpson

    Diterbitkan 2010-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    Frequent MAGE mutations in human melanoma.

    Frequent MAGE mutations in human melanoma. oleh Otavia L Caballero, Qi Zhao, Donata Rimoldi, Brian J Stevenson, Suzanne Svobodová, Sylvie Devalle, Ute F Röhrig, Anna Pagotto, Olivier Michielin, Daniel Speiser, Jedd D Wolchok, Cailian Liu, Tanja Pejovic, Kunle Odunsi, Francis Brasseur, Benoit J Van den Eynde, Lloyd J Old, Xin Lu, Jonathan Cebon, Robert L Strausberg, Andrew J Simpson

    Diterbitkan 2010-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: